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Cy5.5 fluorophore demonstrate specific binding to the 
tumour. Ex vivo NIRF imaging of whole tumours as well 
as NIRF imaging and microscopy of tumour slices con-
firmed the accumulation of the mAb62-Cy5.5 in tumours 
but not in brain tissue. Moreover, mAb62 was conjugated 
to the prodrug-activating enzyme β-D-galactosidase (β-gal; 
mAb62-β-gal). The β-gal activity of the mAb62-β-gal con-
jugate was analysed in vitro on Kv10.1-expressing MDA-
MB-435S cells in comparison to control AsPC-1 cells. We 
show that the mAb62-β-gal conjugate possesses high β-gal 
activity when bound to Kv10.1-expressing MDA-MB-435S 
cells. Moreover, using the β-gal activatable NIRF probe 
DDAOG, we detected mAb62-β-gal activity in vivo over 
the tumour area. In summary, we could show that the anti-
Kv10.1 antibody is a promising tool for the development of 
novel concepts of targeted cancer therapy.
Keywords Antibody targeting Kv10.1 · Ion channel 
Kv10.1 · Non-invasive near infrared fluorescence imaging · 
Preclinical assessment of enzymatic activity · Novel 
therapeutic concepts · Oncology
Introduction
Despite intense medical and research efforts during recent 
decades, cancer is still far from being curable and remains 
a leading cause of death worldwide. Consequently, there 
is still a substantial need to improve the existing and to 
develop alternative strategies to detect and to treat cancer.
Several trends can be observed in cancer research, each 
of extreme importance for both the improvement of current 
tumour diagnostics and the development of novel therapeu-
tic interventions: (1) basic research for better understand-
ing of molecular mechanisms underlying cancer biology, 
Abstract The Kv10.1 (Eag1) voltage-gated potassium 
channel represents a promising molecular target for novel 
cancer therapies or diagnostic purposes. Physiologically, 
it is only expressed in the brain, but it was found overex-
pressed in more than 70 % of tumours of diverse origin. 
Furthermore, as a plasma membrane protein, it is eas-
ily accessible to extracellular interventions. In this study 
we analysed the feasibility of the anti-Kv10.1 monoclo-
nal antibody mAb62 to target tumour cells in vitro and 
in vivo and to deliver therapeutics to the tumour. Using 
time-domain near infrared fluorescence (NIRF) imaging 
in a subcutaneous MDA-MB-435S tumour model in nude 
mice, we showed that mAb62-Cy5.5 specifically accu-
mulates at the tumour for at least 1 week in vivo with a 
maximum intensity at 48 h. Blocking experiments with 
an excess of unlabelled mAb62 and application of the free 
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(2) identification and extensive characterisation of novel 
molecular targets and/or tools and (3) development of 
increasingly sophisticated therapy concepts.
Among many other tumour-specific targets, an increased 
interest has focused on ion channels, as evidence relates 
them to the pathogenesis of malignancies (Lang and Stour-
naras 2014; Pardo and Stuhmer 2014; Arcangeli and Bec-
chetti 2015). Ion channels are transmembrane proteins pre-
dominantly expressed on the cell surface, accessible to the 
extracellular space and therefore to external interventions, 
facilitating their use in diagnosis and therapy (Pardo and 
Stuhmer 2014). The ether-à-go–go 1 (Kv10.1; Eag1) volt-
age-gated potassium channel is a promising target. In con-
trast to its restricted distribution in normal healthy tissue, 
Kv10.1 is significantly overexpressed in many tumour cell 
lines and in a variety of solid tumours from different histo-
logical origins such as breast, colon or cervix (Hemmerlein 
et al. 2006; Mello de Queiroz et al. 2006; Ding et al. 2007a, 
b). Furthermore, cells aberrantly overexpressing Kv10.1 
acquire phenotypical characteristics of malignancy and 
induce strongly aggressive tumour growth in immunodefi-
cient mice (Pardo et al. 1999).
In fact, the efficacy of Kv10.1-targeting antibodies and 
blockers on inhibition/reduction of tumour growth has 
already been described although the exact mechanisms 
remain unclear. Knockdown or blocking of Kv10.1 with 
siRNA or a monoclonal antibody selectively inhibiting 
Kv10.1-mediated potassium currents reduced the prolif-
eration of cancer cell lines and tumour growth in in vivo 
models (Weber et al. 2006; Gomez-Varela et al. 2007; 
Downie et al. 2008). Kv10.1 is not only expressed in the 
primary tumours, but also in brain metastases, where it 
might contribute to tumour progression, because patients 
with brain metastases and moderate Kv10.1 expression 
showed improved survival when treated with different 
Kv10.1-blocking antidepressants (Martinez et al. 2015) 
compared with those treated with other antidepressant 
drugs. Moreover, a fusion protein of single-chain Kv10.1-
targeting antibody and tumour necrosis factor-related 
apoptosis inducing ligand (TRAIL) were shown to not 
only specifically induce apoptosis of tumour cells, but 
also to sensitise them for chemotherapeutic agents (Har-
tung et al. 2011; Hartung and Pardo 2016).
Although Kv10.1-targeting antibodies have already been 
suggested for tumour imaging (Mello de Queiroz et al. 
2006), none of them has been systematically characterised 
for an in vivo application. Here we present an extensive 
characterisation of the Kv10.1-targeting monoclonal anti-
body mAb62 (Hemmerlein et al. 2006) in vitro and in vivo 
using near infrared (NIR) imaging in mouse tumour mod-




Human melanoma MDA-MB-435S and human pancre-
atic carcinoma AsPC-1 cell lines were obtained from 
ATCC (Rockville MD). Cells were cultured in RPMI 1640 
medium with GlutaMAX supplemented with 10 % fetal 
calf serum (FCS; Invitrogen).
Real‑time PCR
Total RNA was extracted with the RNeasy mini kit (Qia-
gen) following the manufacturer’s recommendations; 5 µg 
of total RNA was used for cDNA synthesis with Super-
Script (Invitrogen).
Real-time PCR was performed with 100 ng cDNA in a 
LightCycler 480 (Roche) as previously described (Hartung 
et al. 2011). Human transferrin receptor was used as a ref-
erence. The specific mRNA content was determined using 
the LightCycler 480 software (Roche). All measurements 
were performed in triplicate.
Antibody conjugates
The monoclonal mouse antibody mAb62 (IgG κ2b) gen-
erated in our group (Gomez-Varela et al. 2007; Ramos 
Gomes et al. 2015) was labelled with Cy5.5 (Cy5.5 
maleimide monoreactive dye; Amersham/GE Health-
care Life Sciences) using a standard protocol, resulting in 
mAb62-Cy5.5 (dye/protein ratio of ~0.7).
The coupling of mAb62 with β-D-galactosidase (G4155; 
Sigma) resulting in mAb62-β-gal was performed by 
Squarix GmbH (Marl, Germany).
Antibody‑binding assay
The 96-well plates were coated overnight at 4 °C with 
500 ng of h1x antigen (Hemmerlein et al. 2006) in 100 µl 
Tris-buffered saline (TBS). After blocking with 200 µl 3 % 
bovine serum albumin (BSA) in TBS for 1 h at RT, 1 µg of 
mAb62-Cy5.5 antibody in 100 µl TBS was added to each 
well and plates were incubated at RT for 2 h. For com-
petitive binding studies, increasing amounts of unlabelled 
mAb62 (0.04–4 µg/well) were added to the wells and incu-
bated together with 1 µg of mAb62-Cy5.5. Subsequently, 
the plates were washed 3 × 10 min with 0.05 % Tween 20 
in TBS, and 100 µl TBS buffer was added to each well. The 
plates were scanned in an Odyssey Infrared Imager (LI-
COR Biosciences) using 700 nm excitation. To quantify the 
binding, a circular ROI of identical size was drawn over the 
centre of each well and the average fluorescence intensity 
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over the area was measured in arbitrary units (a.u.). The 
experiment was performed in duplicate.
Immunofluorescence staining and microscopy
Prior to the experiments 5 × 105 AsPC-1 or MDA-MB-
435S cells per well were grown overnight on coverslips in 
24-well plates.
For immunofluorescence staining, cells were fixed for 
10 min with ice-cold 4 % paraformaldehyde (PFA), perme-
abilised for 10 min with 0.5 % Triton X-100 in phosphate-
buffered saline (PBS) and washed three times with PBS. 
Then cells were blocked for 10 min with 10 % BSA in PBS 
and incubated with mAb62 (5 µg in 200 µl of 10 % BSA) in 
PBS for 2 h at room temperature, washed three times each 
for 10 min with 0.1 % Tween 20 in PBS and stained with 
anti-mouse Alexa Fluor 488 antibody (Invitrogen; Molecu-
lar Probes) for 30 min at room temperature. Finally, cells 
were washed three times for 10 min with 0.1 % Tween 20 
in PBS, rinsed with PBS and mounted with ProLong Gold 
Antifade Reagent with DAPI (Invitrogen).
For staining of living cells, the medium was replaced by 
fresh culture medium containing 10 µg/ml mAb62-Cy5.5 
and cells were left at 37 °C for another 3 h. Subsequently, 
cells were washed with PBS, fixed in 4 % PFA/PBS and 
mounted with ProLong Gold Antifade Reagent with DAPI 
(Invitrogen).
Cells were imaged with an Axiovert 200 M fluores-
cence microscope (Carl Zeiss) equipped with a NIR-sen-
sitive ORCA-ER digital camera (Hamamatsu) with the 
following filter settings: 365 ± 12.5 nm excitation and a 
445 ± 25 nm emission filter for DAPI, 450–490 nm excita-
tion and 515–565 nm emission filter for Alexa Fluor 488 
and 640 ± 15 nm excitation and 690 ± 25 nm emission 
filter for Alexa-Fluor 647. Image generation and processing 
were performed with the AxioVision Rel.4.6 and ImageJ 
software (Collins 2007), respectively.
In vitro imaging of β‑gal activity
1 × 105 of AsPC-1 or MDA-MB-435S cells was plated in 
96-well plates and allowed to attach for 24 h. The medium 
was then replaced with 50 µl of staining buffer (2 % FCS, 
0.1 % NaN3 in PBS) containing 2.5 µg of mAb62-β-gal and 
the cells were incubated with the conjugate for 30 min on 
ice. After four washing steps, each by immersing the entire 
plate for 1 min into a tray containing 1 l of washing buffer 
(130 mM NaCl, 10 mM HEPES pH 7.4, 5 mM KCl, 1 mM 
CaCl2 and 1 % FCS), 100 µl of freshly prepared substrate 
solution containing 0.1 % NaN3, 1 % BSA, 2 mM MgCl2 
and 2 mg/ml chlorophenol red-β-D-galactopyranoside 
(CPRG; Sigma) in PBS was added to each well and the 
increase of absorbance at 570 nm over time was measured 
immediately in a Wallac 1420 Victor2 Microplate Reader 
(Perkin Elmer). Five wells were analysed per measurement.
Animal models
Female athymic nude NMRI-Fox1nu/nu mice (Winkelmann) 
were used for the in vivo imaging experiments. Animals 
were handled according to German ethics regulations for 
animal experimentation and all protocols were approved by 
the administration of Lower Saxony, Germany.
Mice were anaesthetised with 1.8–2.0 % inhaled iso-
flurane and either 1 × 107 MDA-MB-435S or 1 × 106 
AsPC1 cells suspended in 100 µl of PBS were subcutane-
ously transplanted into the right flank of the mice. Mice 
were inspected twice weekly for tumour development, loss 
of body weight and general condition. All animals toler-
ated the procedure well. At the end of the experiment ani-
mals were euthanized by isoflurane overdose and cervical 
dislocation.
NIRF imaging
To reduce the fluorescence background, mice received 
chlorophyll-reduced GLP Nafag 890 food (Provimi Kliba 
AG) for ~1 week before NIRF imaging. All in vivo analy-
ses were preceded by native scans.
Mice were anaesthetised with 1.8–2.0 % inhaled isoflu-
rane and injected intravenously (i.v.) via the tail vein with 
either 25 µg of mAb62-Cy5.5, 25 µg of mAb62-Cy5.5 
together with 50 µg of unlabelled mAb62 or 1.2 µg of 
Cy5.5 (Amersham) in 150 µl NaCl 0.9 %. Animals were 
scanned with the Optix MX2 (ART) time-domain imaging 
system in vivo at the indicated times. At the end of experi-
ments, mice were sacrificed and the excised organs were 
imaged ex vivo.
Cy5.5 fluorescence was obtained with an excitation at 
670 nm in combination with a 700-nm long-pass emission 
filter. Scans were performed with a 1.5 mm (whole-body 
scans and organ scans) or 1.0 mm (region of interest, ROI) 
raster and a point integration time of 0.7 s. Data were ana-
lysed with OptiView software (ART).
Unspecific signals were identified by lifetime measure-
ment. Lifetimes (LTs) that deviated from measured values 
of the ligand-dye conjugates in vitro were considered as 
background, which was removed from intensity images by 
setting lifetime gates (Napp et al. 2010).
For in vivo measurement of β-gal activity (Tung et al. 
2004) 25 µg of mAb62-β-gal was applied i.v. to tumour-
bearing mice. After ~24 h, isoflurane-anaesthetised animals 
received i.v. 5 mg of DDAOG [(9H-(1,3-dichloro-9,9-di-
methylacridin-2-One-7-yl) β-D-galactopyranoside), Molec-
ular Probes/Thermofisher] in 150 µl of 0.9 % NaCl/DMSO 
(50/50). Mice were repetitively scanned over ~3.5 h with 
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the Optix MX2 directly after injection using a 635 nm exci-
tation laser and a 670 ± 20 nm emission filter, 1.0–1.5 mm 
raster and a point integration time of 0.7 s.
Imaging on tissue slices
Tumour and brain tissue from mice injected with mAb62-
Cy5.5 24 h prior to the dissection were fixed over night 
with 4 % PFA and cut on a vibratome (Leica VT1000 S) 
into 100 µm-thick sections. The tissue sections were then 
mounted onto microscope slides and imaged with the flat-
bed scanner Odyssey NIRF imager (LI-COR Biosciences) 
using 700 nm settings.
Statistics
The significance was analysed by two-tailed unpaired Stu-
dent’s t test using the PAST programme (Hammer et al. 
2001). Statistical significance was defined as p ≤ 0.05.
Results
Binding of the anti‑Kv10.1 antibody mAb62‑Cy5.5 
to Kv10.1 in vitro
The mouse monoclonal antibody (IgG κ2b) mAb62 was 
obtained by immunisation using a fusion protein h1x that 
contains the pore-forming loop and the tetramerisation 
domain of Kv10.1 (Hemmerlein et al. 2006; Gomez-Varela 
et al. 2007). Antibody specificity to Kv10.1 was determined 
by surface plasmon resonance against several other chan-
nels and on tissues from knockout mice. In vitro evaluation 
of mAb62 for efficient targeting and monitoring of tumours 
was performed with the MDA-MB-435S cell line, which is 
known to express Kv10.1 and which was used by our group 
in previous in vivo studies (Gomez-Varela et al. 2007; 
Downie et al. 2008; Hartung and Pardo 2016). AsPC1 cells 
were chosen as a control and the Kv10.1 expression levels 
were verified in both cell lines by real-time PCR.
As shown in Fig. 1a high levels of Kv10.1 expression 
were detected in the MDA-MB-435S cells, whereas no 
Kv10.1 expression was found in the AsPC-1 cells.
Furthermore, both cell lines were grown on glass cov-
erslips and stained with mAb62, followed by the detec-
tion with an anti-mouse secondary antibody labelled with 
Alexa Fluor 488. As expected, a clear staining was detected 
only on Kv10.1 high-expressing MDA-MB-435S but not on 
AsPC1 cells (Fig. 1b).
For in vivo imaging, the antibody was labelled with 
Cy5.5, resulting in mAb62-Cy5.5. Binding of the conju-
gate to the h1x antigen was analysed in an immunoassay, 
in which the fluorescence intensity upon binding of the 
Cy5.5-labelled antibody to an h1x antigen-coated plate was 
measured in the Odyssey NIRF imaging system. As shown 
in Fig. 1c, mAb62-Cy5.5 specifically binds to the Kv10.1 
epitope in vitro, demonstrated by high average fluorescence 
intensity. Moreover, upon addition of increasing amounts 
of free mAb62 (0.04, 0.4 and 4 µg), binding of mAb62-
Cy5.5 to the h1x epitope was reduced in a concentration-
dependent manner. While the lowest concentration of 
0.04 µg showed no effect on the average fluorescence inten-
sity, the binding to h1x could be almost completely blocked 
with 4 µg of unlabelled mAb62.
Further, we analysed whether mAb62-Cy5.5 conju-
gate specifically binds to Kv10.1-expressing cells. For this 
purpose, living cells were incubated with mAb62-Cy5.5 
for 3 h in cell culture medium. As shown in Fig. 1d, bind-
ing and uptake were observed only in Kv10.1-expressing 
MDA-MB-435S cells, whereas no mAb62-Cy5.5-derived 
fluorescence was detected in the control AsPC-1 cells that 
showed no Kv10.1 expression in real-time PCR. In MDA-
MB-435S cells the most intense fluorescence signals were 
detected as foci, which probably correspond to the internal-
ised probe.
In vivo binding of the mAb62‑Cy5.5 
to Kv10.1‑expressing tumours
In order to characterise the capability of mAb62 for in vivo 
tumour imaging and/or targeting, MDA-MB-435S and 
AsPC-1 cells were subcutaneously transplanted into nude 
mice. After the tumours reached volumes of ~200 mm3, 
mice were injected with 25 µg of mAb62-Cy5.5 through 
the tail vein and imaged 24 h later. As shown in Fig. 2a, a 
strong and specific accumulation of the fluorescent probe 
to the Kv10.1-expressing MDA-MB-435S tumours was 
detected by Optix MX2 in vivo. Interestingly, AsPC-1 
tumour-bearing mice also showed an increase of the fluo-
rescence intensity over the tumour area after probe injec-
tion, although the signals were much weaker. This fluores-
cence can be explained by the presence of the probe in the 
circulating blood and/or by the unspecific accumulation of 
the antibody in the tumour due to leaky vessels. However, 
some upregulation of Kv10.1 expression within the AsPC-1 
tumour tissue cannot be excluded.
Twenty-four hours after probe injection mice were killed 
and the excised tumours were scanned ex vivo (Fig. 2b). 
As expected, the fluorescence intensity detected over the 
Kv10.1-expressing MDA-MB-435S tumour at 24 h was 
much higher than the one detected over the control AsPC1 
tumour.
Next, we characterised the binding and distribution 
pattern of mAb62-Cy5.5 in MDA-MB-435S tumour-
bearing mice. Representative data for ventral and dor-
sal scans obtained at 24 h after probe administration are 
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Fig. 1  In vitro analysis of mAb62-Cy5.5 binding specificity to 
Kv10.1-expressing cells. a Real-time PCR shows high Kv10.1 expres-
sion in MDA-MB-435S cells in comparison to the AsPC-1 cells. b 
Staining of fixed MDA-MB-435S (left) and AsPC-1 (right) cells with 
mAb62, followed by anti-mouse Alexa 488-labeled secondary anti-
body is shown. Specific binding of the mAb62 could only be detected 
on Kv10.1-expressing MDA-MB-435S cells (green; arrows), but not 
on the AsPC-1 cells. c Fluorescence based immunoassay shows that 
mAb62-Cy5.5 specifically binds to the Kv10.1 epitope h1x. While 
high average fluorescence intensities can be detected upon incubation 
of a h1x-coated plate with mAb62-Cy5.5, binding can be reduced by 
co-incubation with an excess of unlabelled mAb62 in a concentra-
tion-dependent manner. Fluorescence intensity is shown in arbitrary 
units (a.u.). The experiment was performed in duplicate. d Immuno-
fluorescence staining of live MDA-MB-435S and AsPC-1 cells with 
mAb62-Cy5.5 demonstrates strong mAb62-Cy5.5-derived fluores-
cence (red; arrows) only in the Kv10.1-expressing MDA-MB-435S 
cells. Nuclei are shown in blue. Bars 20 µm
Fig. 2  Binding of mAb62-Cy5.5 to Kv10.1-expressing tumours. 
Representative a in vivo and b ex vivo scans of MDA-MB-435S and 
AsPC-1 subcutaneous tumours 24 h after i.v. injection of mAb62-
Cy5.5. High fluorescence intensity was observed over the Kv10.1-
expressing MDA-MB-435S tumour (arrow), whereas the control 
AsPC1 tumour (arrow) showed much lower fluorescence in both 
in vivo and ex vivo scans. Intensity is depicted in normalised counts 
(NC)
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shown in Fig. 3. In prescans performed before probe 
administration, a homogeneous autofluorescence back-
ground over the whole body was detected as well as a 
stronger background over the stomach (S) and gastroin-
testinal tract (G) (Fig. 3; upper panels). As shown in the 
middle panels of Fig. 3, autofluorescence lifetimes over 
the whole body were much shorter (0.6–0.8 ns) than the 
ones determined over the gastrointestinal tract (1.9–
2.3 ns). In our experience the fluorescence observed over 
the stomach and intestinal tract probably derives from 
food, despite feeding the animals with a chlorophyll-
depleted diet (data not shown). The background auto-
fluorescence over the subcutaneous tumours (T; white 
circle) had slightly higher intensity and a longer lifetime 
(0.9 ns) than whole-body background autofluorescence 
levels.
Twenty-four hours after application of mAb62-Cy5.5 
strong fluorescence over the tumour could be detected in 
whole-body scans. Moreover, the fluorescence intensity 
over the whole body increased, including the area over the 
stomach and liver as well as the area over the head, vis-
ible on the dorsal scans. The lifetime of 1.6 ns measured 
over the tumour was comparable to the probe’s lifetime 
measured in vitro (1.5 ns; data not shown) and confirms 
the specificity of the signal detected in vivo. The lifetime of 
the fluorescence measured over the background was longer 
(1.4–1.6 ns) in comparison to that of the prescans (Fig. 3 
middle panel), suggesting that the higher background 
Fig. 3  In vivo characterisa-
tion of mAb62-Cy5.5-derived 
fluorescence. Representative 
intensity and lifetime maps of 
an MDA-MB-435S tumour-
bearing mouse are shown before 
(left; prescan) and 24 h after 
i.v. injection of mAb62-Cy5.5, 
scanned ventrally and dorsally 
in vivo with the Optix MX2. 
Upper panel shows fluorescence 
intensity scans with a low back-
ground autofluorescence and 
signals detected over the stom-
ach (S) and gastrointestinal tract 
(G). Strong fluorescence over 
the Kv10.1-expressing tumour 
(T) as well as an increase in the 
overall background was meas-
ured 24 h after application of 
mAb62-Cy5.5. Lifetime (mid-
dle panel) of the background 
fluorescence was 0.6–0.8 ns 
in the prescans and increased 
to 1.4–1.6 ns after applica-
tion of the probe, whereas the 
fluorescence lifetime over the 
gastrointestinal tract remained 
the same (1.9–2.3 ns). The 
lower panel shows fluorescence 
intensity maps after setting the 
lifetime gate to 1.50–1.65 ns. 
Note that not only the high 
fluorescence intensity over the 
tumour area but also some of 
the fluorescence over the whole 
body remained after gating. 
Fluorescence is shown in nor-
malised counts (NC)
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was most likely because of the presence of the circulating 
mAb62-Cy5.5 probe. The average fluorescence lifetime 
over the gastrointestinal tract did not change when com-
pared to the prescans.
In order to select the specific probe-derived fluores-
cence over the tumour, we applied a lifetime gate of 1.50–
1.65 ns to the raw scan data. As shown in the lower panel 
of Fig. 3, we removed most of the background fluorescence 
from the prescans. As expected, the strong probe-derived 
fluorescence over the tumour area remained on the gated 
scans. Moreover, even after gating, fluorescence was still 
observed over the whole body, probably deriving from the 
free circulating probe.
In order to test the specificity of the mAb62 in vivo 
in more detail, either 25 µg of mAb62-Cy5.5, 25 µg of 
mAb62-Cy5.5 together with a twofold excess (50 µg) of 
mAb62 (blocking experiment) or 1.2 µg of free Cy5.5 
fluorophore was injected into MDA-MB-435S tumour-
bearing mice. Time-domain fluorescence imaging of the 
tumour areas was performed over time, before (prescan), 
4 h after as well as 1, 2, 3, 4, 7, 9 and 14 days after probe 
application. As shown in the representative images of the 
tumour areas in Fig. 4a, mAb62-Cy5.5-derived fluores-
cence was detected at the tumour site for at least 1 week 
with a maximum intensity measured 2 days post injection. 
Blocking experiments with a twofold excess of unlabelled 
mAb62 as well as application of the free Cy5.5 fluoro-
phore (Fig. 4b) resulted in significantly lower fluores-
cence intensities at all time points between 1 and 14 days 
after injection and therefore confirmed the binding speci-
ficity of mAb62-Cy5.5 to Kv10.1-expressing MDA-MB-
435S tumours.
Fig. 4  In vivo time-domain fluorescence imaging of subcutaneous 
Kv10.1-expressing MDA-MB-435S tumours in mice injected with 
mAb62-Cy5.5 a Representative series of scans over the tumour areas 
acquired at different time points after injection of 25 µg of mAb62-
Cy5.5 (n = 8 for 1 day, 2 days and 7 days; n = 6 for 4 h, 3 days 
and 4 days; n = 5 for 9 days and n = 3 for 14 days), of 25 µg of 
mAb62-Cy5.5 together with unlabelled mAb62 (n = 3) and of 1.2 µg 
of Cy5.5 (n = 5) are shown. b Box plot showing significantly higher 
average fluorescence intensities (NC) measured over time over the 
MDA-MB-435S tumours of mice injected with 25 µg mAb62-Cy5.5 
compared to the tumours of mice injected with 25 µg of the mAb62-
Cy5.5 together with twofold excess (50 µg) of mAb62 (blocking 
experiment) or with 1.2 µg of free Cy5.5 fluorophore (*p < 0.05)
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Mice were killed and tumour as well as liver, spleen, kid-
ney and brain was extracted and scanned ex vivo with the 
Optix MX2. As shown in Fig. 5a, ex vivo imaging confirmed 
that only the tumours of mice injected with mAb62-Cy5.5 
showed strong fluorescence, but not tumours of the controls 
co-injected with the blocking antibody. No probe-derived 
fluorescence was observed in any other tested organs.
As Kv10.1 is physiologically expressed in the brain, it 
was important to analyse whether mAb62-Cy5.5 is able 
to pass the blood-brain barrier and therefore detectable on 
brain tissue slices. Tumours and brains of mice injected 
with mAb62-Cy5.5 were thus embedded in paraffin and 
slices were scanned with the Odyssey imaging system 
(Fig. 5b). Strong fluorescence intensity was observed on 
the tumour slice, whereas no signal could be detected on 
the brain tissue slice. NIR fluorescence microscopy of 
tumour slices confirmed mAb62-Cy5.5-derived signals 
within tumour tissues (Fig. 5c).
Kv10.1‑targeting antibody as a tool for delivery of a 
drug‑activating enzyme to the tumour: proof of concept
Finally, in order to study the feasibility of the mAb62 to 
deliver diagnostic tools or therapeutics to the tumour, we 
conjugated the antibody with the drug-activating enzyme, 
β-D-galactosidase (mAb62-β-gal) and analysed its binding 
as well as measured the specific β-gal activity at the tumour 
cells in vitro and at the tumour site in vivo.
To this end, Kv10.1-expressing MDA-MB-435S and 
control AsPC-1 cells were incubated for 30 min in vitro 
with mAb62-β-gal as well as with the non-conjugated 
mAb62 as a negative control. After careful washing of the 
unbound conjugate, cleavage of the β-gal substrate CPRG 
to chlorophenol red (570 nm absorbance) by the bound 
β-gal conjugate was measured. A positive reaction was 
only detected on the MDA-MB-435S cells incubated with 
the mAb62-β-gal construct (Fig. 6a). The control AsPC-1 
Fig. 5  Ex vivo imaging of 
organs from MDA-MB-435S 
tumour-bearing mice after injec-
tion of mAb62-Cy5.5. a Tissue 
distribution of mAb62-Cy5.5 
(25 µg; left) and mAb62-Cy5.5 
co-injected with an excess of 
unlabelled mAb62 (50 µg; right) 
is shown (T tumour, B brain, L 
liver, S spleen, K kidney). Note 
that tumours (shown in insets) 
were scanned separately and 
are shown as 2 × larger images 
in comparison to the other 
organs. b Scans of slices of 
primary tumour and brain from 
mouse injected with 25 µg of 
mAb62-Cy5.5 performed with 
the Odyssey imaging system are 
presented. c NIRF microscopy 
of tumour slices confirmed the 
presence of mAb62-Cy5.5 (red) 
within tumour (arrows). Nuclei 
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cells incubated with the mAb62-β-gal showed only a very 
low cleavage of CPRG to chlorophenol red. As expected, 
β-gal activity was not measurable on the cells incubated 
with the unconjugated mAb62.
Finally, the in vivo activity of mAb62-β-gal was meas-
ured in MDA-MB-435S tumour-bearing mice (n = 2) using 
the β-gal substrate DDAOG, which shifts its excitation 
maximum from 465 to 646 nm upon cleavage to DDAO. In 
the first step, mAb62-β-gal was applied to MDA-MB-435S 
tumour-bearing mice and allowed to bind to the tumour for 
24 h, the time when the mAb62-Cy5.5 achieved the high-
est tumour accumulation. Subsequently, we administered 
DDAOG i.v. and measured the fluorescence intensity of 
the DDAO over the tumour area over ~3.5 h. As shown in 
Fig. 6b, fluorescence intensity increased within the first 2 h 
after application, confirming that mAb62-β-gal binds to 
the tumour and the enzyme galactosidase remains active 
in vivo at the tumour site.
Discussion
Along with their role as critical mediators of numerous 
physiological processes, ion channels are increasingly in 
the focus of oncology. Due to their role in the regulation 
of various steps of neoplastic progression they have been 
suggested as promising tools for cancer treatment and 
diagnosis.
Fig. 6  Binding and enzymatic activity of mAb62-β-gal in vitro and 
in vivo. a MDA-MB-435S and AsPC-1 cells were incubated with 
β-gal conjugated mAb62 (mAb62-β-gal) as well as with mAb62 as 
control. Cleavage of the β-gal substrate CPRG to chlorophenol red 
(570 nm absorbance) was measurable only in the MDA-MB-435S 
cells incubated with the conjugate, showing that mAb62-β-gal spe-
cifically binds to Kv10.1-positive cells and that the enzyme is active 
in vitro. b mAb62-β-gal was applied to MDA-MB-435S tumour-bear-
ing mice (n = 2) and allowed to bind to the tumour for 24 h; 5 mg 
of DDAOG was administered i.v. and cleavage to DDAO resulting in 
an excitation shift from 465 to 646 nm was imaged with Optix MX2. 
Fluorescence intensity (NC) of the DDAO measured over the tumour 
increased within the first 3 h after application of DDAOG, confirming 
that mAb62-β-gal binds to the tumour and the enzyme remains active 
in vivo
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Here we present a systematic characterisation of the 
monoclonal antibody mAb62, targeting the Kv10.1 potas-
sium channel in vivo in a nude mouse subcutaneous tumour 
model as a potential tool for cancer targeting. This particu-
lar antibody specifically recognises the full-length Kv10.1, 
but not its shorter splice variants, which do not display the 
corresponding epitope (Ramos Gomes et al. 2015). By 
NIRF imaging we showed a selective binding of the NIR 
fluorescently labelled mAb62 to Kv10.1-expressing MDA-
MB-435S tumours in vivo, with a peak at 2 days post injec-
tion, which could be blocked by an excess of unlabelled 
mAb62. Furthermore, we show that the antibody is detect-
able at the tumour site for up to 2 weeks in vivo. Compa-
rable binding of antibodies up to several days post injec-
tion and with maximum intensities between 1 and 2 days 
has previously been shown by in vivo fluorescence imaging 
(Napp et al. 2010). By contrast, smaller molecules, such 
as RGD peptides, usually show a maximum fluorescence 
intensity as early as a few hours post injection, mainly due 
to more rapid renal clearance (Mathejczyk et al. 2011).
We have chosen NIRF imaging to assess the binding and 
biodistribution of mAb62 as this technique utilises non-ion-
ising radiation and therefore has the important advantage 
of being harmless, in contrast to other functional imag-
ing modalities such as PET or SPECT. In addition, it is a 
simple, quick and relatively cheap method, which deliv-
ers a variety of information such as on target expression, 
probe biodistribution and tissue characteristics such as pH 
and oxygen levels or enzymatic activity (Napp et al. 2010, 
2011; Mathejczyk et al. 2011, 2012). Moreover, the use of 
NIR light allows for relatively deep tissue penetration of up 
to 2 cm, which means that even deeply located structures, 
such as a fluorescently labelled pancreatic tumour, can be 
easily detected within a living mouse (Napp et al. 2010).
Since we applied a subcutaneous tumour mouse model, 
in which tumours are visible with the naked eye, the 
detected fluorescence could be clearly located to the tumour 
site. In contrast, orthotopically transplanted tumours, espe-
cially those located deep within the body, as for example 
pancreatic cancer, are often much more difficult to correlate 
to anatomical structures. In such cases NIRF imaging data 
have to be overlaid with data obtained from an anatomical 
imaging modality such as CT, as already shown for ortho-
topic pancreatic or mammary tumours (Dullin et al. 2009).
We confirmed the specificity of the fluorescence signals 
by showing that the fluorescence detected over the tumour 
24 h after injection of mAb62-Cy5.5 had almost the same 
lifetime (1.6 ns) as the one of the mAb62-Cy5.5 measured 
in vitro (1.5 ns). The fact that the same lifetime was also 
measured all over the body, except the gastrointestinal tract, 
is most likely due to the probe still present in the circula-
tion and not yet completely cleared from the blood. This 
is not surprising as whole antibodies such as the mAb62 
are known to have relatively long circulation times (Wang 
et al. 2008). The long fluorescence lifetime of 1.9–2.3 ns 
over the gastrointestinal tract, which was also observed in 
the pre-contrast scans, was already described in our previ-
ous studies and can be explained by the autofluorescence 
of digested food despite feeding the mice with chlorophyll-
depleted pellets (Napp et al. 2010).
The most likely source of harmful effects from tools 
targeting ion channels is the direct influence they could 
have on the physiology of excitable tissue. As Kv10.1 is 
physiologically expressed in the central nervous system, 
and because previous immunohistochemistry experiments 
(Hemmerlein et al. 2006) showed specific binding of 
mAb62 to rat brain slices, it was of extreme importance to 
exclude the diffusion and binding of the i.v. applied mAb62 
to the brain tissue. Using in vivo fluorescence imaging as 
well as ex vivo imaging of the excised organs and tissue 
slices we could show that mAb62-Cy.5.5 did not accumu-
late within brain tissue. The slight increase of the fluores-
cence intensity over the cranial area in in vivo dorsal scans 
performed 24 h after probe injection was comparable to the 
overall increase of the whole-body fluorescence. This con-
firms that the signals measured over the brain were most 
probably due to the circulating probe rather than to the spe-
cific accumulation of mAb62-Cy.5.5 in the brain. In gen-
eral, whole antibodies show a relatively low distribution 
to the brain, with brain-to-plasma ratios as low as 1:500, 
mainly due to the blood brain barrier and rapid turnover of 
brain interstitial fluids. This makes whole antibodies often 
more suitable for tumour targeting than smaller ligands, 
especially when brain targeting is not desired (Wang et al. 
2008). Monoclonal antibodies are increasingly applied in 
clinical practice, e.g., for treatment of cancer, transplant 
rejection or infectious diseases (Catapano and Papadopou-
los 2013). In general, their off-target toxicity is relatively 
low and mostly restricted to hypersensitivity reactions and 
immunogenicity, which can be easily reduced by produc-
tion of genetically engineered chimeric (mouse-human) or 
humanised monoclonal antibodies.
In a proof-of-concept experiment we showed that the 
mAb62-β-gal construct can specifically deliver drug-activat-
ing enzyme to the tumour. We confirmed that the mAb62-β-
gal conjugate not only specifically binds to Kv10.1-express-
ing cells in vitro and accumulates within Kv10.1-expressing 
tumours, but also retains its enzymatic activity on tumour 
cells, both in vitro and in vivo. Therefore, mAb62 conju-
gated to the enzyme β-D-galactosidase could represent a 
tool for tumour-specific therapies such as the antibody-
directed enzyme prodrug therapy (ADEPT; Fig. 7) (Alves 
et al. 2009) in which a tumour-targeting ligand carries a 
drug-activating enzyme to the tumour tissue and a subse-
quently administered non-toxic prodrug is locally converted 
to a cytotoxic drug by the tumour-bound enzyme.
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Here we show the use of fluorescence imaging to evalu-
ate the specificity of the antibody binding or the activity of 
the antibody-enzyme conjugate at the tumour site. Addi-
tional anatomical imaging, such as CT, could be considered 
for anatomical correlation as has been previously shown 
(Alves et al. 2009). Alternatively, bioluminescence imaging 
could be applied upon transplantation of genetically modi-
fied tumour cells to monitor therapeutic efficacy by assess-
ing tumour progression in vivo over time.
Antibodies and small molecule compounds targeting 
Kv10.1 or blocking Kv10.1 channel function have already 
been proposed for therapeutic purposes (Pardo et al. 2012). 
A single chain antibody scFv62, derived from mAb62, 
was fused to the tumour necrosis factor (TNF)-related 
apoptosis-inducing ligand (TRAIL) and was shown to 
induce apoptosis and to sensitise prostate cancer cells to 
chemotherapeutics in vitro (Hartung et al. 2011; Hartung 
and Pardo 2016). Another monoclonal antibody, function-
ing as a channel blocker and able to inhibit Kv10.1 cur-
rent, was shown to not only reduce the growth of cancer 
cells in vitro, but also tumour progression in vivo in sub-
cutaneous MDA-MB-435S xenografts and in human pan-
creatic cancer explants (Gomez-Varela et al. 2007). Simi-
larly, astemizole, a small-molecule open channel blocker of 
Kv10.1, was reported to inhibit growth of Kv10.1-express-
ing cancer cells in vitro and in vivo (Downie et al. 2008; 
Garcia-Quiroz et al. 2014; Chavez-Lopez et al. 2015).
Both, monoclonal antibodies and small molecules are 
promising tools for cancer targeting, but the individual 
advantages and disadvantages of each have to be taken 
into consideration (Imai and Takaoka 2006). A major 
impediment of monoclonal antibodies is that they are typi-
cally produced in mice and therefore commonly induce an 
immune response in humans known as a human anti-mouse 
antibody (HAMA). This limits their repeated use in most 
patients, though this problem can currently be solved rela-
tively easily by using humanised antibodies. The large size 
of whole antibodies (~150 kDa) results in prolonged blood 
half-lives and slow hepatic clearance, whereas the many 
times smaller molecules are usually cleared much faster 
and via renal excretion. For example, the half-life of cetuxi-
mab, a chimeric monoclonal antibody targeting the epithe-
lial growth factor receptor (EGFR) and clinically approved 
for treatment of several cancer types, is between 3.1 and 
7.8 days in humans, whereas the half-life of a small mol-
ecule drug targeting the same molecule EGFR is only 36 h, 
requiring a different dosing scheme (Imai and Takaoka 
2006). This frequently influences the administration route: 
while monoclonal antibodies are usually injected intrave-
nously, small molecules are often administered orally. Fur-
thermore, and probably most importantly, cell membranes 
are generally impermeable to IgGs whereas many small 
molecules can easily pass into the cell. This means that 
whole antibodies most of the time act on cell surface tar-
gets, such as the Kv10.1, while small molecule drugs more 
often target intracellular molecules.
Ion channels are especially interesting targets for 
therapeutic interventions as they are easily accessible 
from the extracellular milieu. The monoclonal antibody 
used in our study may not only be a valuable tool for 
ADEPT, but can also be used for the targeted delivery 
of toxic compounds to the tumours, like radioligands or 
Fig. 7  Schematic representation of Kv10.1-based antibody-directed 
enzyme prodrug therapy (ADEPT). Antibody targeting Kv10.1 can 
be used to carry a drug-activating enzyme such as β-D-galactosidase 
(β-gal) to the tumour. Specific binding of the antibody-enzyme com-
plex at the tumour site results in spatially restricted cleavage of the 
nontoxic prodrug to an active anticancer drug
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bacterial toxins (Fig. 8). These so-called immunotoxins 
are already used in clinical trials and some show prom-
ise for further clinical evaluation. The concept of fusing 
antibodies to apoptosis-inducing ligands (e.g., TRAIL) 
has the advantage of low immunogenicity, because the 
ligands are a part of the immune system and, unlike tox-
ins, will not be detected as foreign substances. An alter-
native approach is the selective activation of the host 
immune system and initiation of an immune response in 
the tumour. For this purpose, bispecific antibodies can be 
used that simultaneously target a tumour-specific antigen 
and the CD3 receptor to transport and activate cytotoxic 
T cells to and at the tumour site. Also antibody-cytokine 
fusion proteins enhance the direct antitumour effect of 
the antibody and concentrate the cytokine (e.g. IL-2) in 
the tumour microenvironment without causing severe 
toxic side effects of systemic high-dose cytokine admin-
istration. A combination of different antibody constructs 
may be the right course for an effective therapeutic strat-
egy in the future.
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